75A50325C00019↗
Glaxosmithkline, LLC received this contract from Aspr/Orm-Sns, Office of Assistant Secretary for Preparedness and Response: $45.50M obligated so far for drugs and biologicals. It runs to 2028-09-29, or to 2030-09-29 if every option is exercised.
Key facts · data as of Oct 22, 2026
- Recipient
- Glaxosmithkline, LLC
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Aspr/Orm-Sns (75A503)
- Obligated to date
- $45.50M
- Potential value
- $63.70M
- Ends
- 2028-09-29
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75A50325C00019, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75A50325C00019_7505_-NONE-_-NONE-
Glaxosmithkline, LLC: all federal awards · Department of Health and Human Services: spending · Aspr/Orm-Sns: what it buys · The follow-on: recompete brief
RELENZA (ZANAMIVIR) ROTADISK, 5MG
Up for re-bid: ends 2028-09-29. Recompete brief →
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Pharmaceutical Preparation Manufacturing (NAICS 325412)
- Contracting office
- Aspr/Orm-Sns (75A503)
- Competition
- Not competed · 1 offer received
- Pricing
- Firm fixed price
- How it was bought
- Standalone contract
- Where the work is
- Durham, NC · district NC-04
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
4 actions since 2025-09-26. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-25 | P00003 | Option exercised | $18.20M | EXERCISE OPTION FOR RELENZA (ZANAMIVIR) ROTADISK, 5MG |
| 2026-08-18 | P00002 | Option exercised | $9.10M | EXERCISE OPTION FOR RELENZA (ZANAMIVIR) ROTADISK, 5MG |
| 2026-06-23 | P00001 | Option exercised | $9.10M | RELENZA (ZANAMIVIR) ROTADISK, 5MG |
| 2025-09-26 | 0 | $9.10M | RELENZA (ZANAMIVIR) ROTADISK, 5MG |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗